This heightened sensitivity can contribute to feelings of sickness
Last updated July 14, 2026 Key takeaways The current FDA Wegovy label, revised February 2026, gives injectable semaglutide an elimination half-life of approximately 1 week
Other statin drugs, such as rosuvastatin and fluvastatin, can increase GSH and/or GPX in the myocardium to alleviate ISO-mediated myocardial injury [230, 231]
Vildagliptin: peripheral oedema and nasopharyngitis Interactions Clinically significant drug interactions are described as follows: *Sitagliptin is metabolised primarily by CYP3A4, in severe renal impairment metabolism plays a more significant role in sitagliptin elimination, therefore potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase sitagliptin plasma levels in severe renal impairment The blood glucose-lowering effects of DPP-4 inhibitors may also be enhanced or inhibited by other substances: References DPP-4 inhibitors | Prescribing information | Diabetes type 2 | CKS | NICE Sitagliptin 100 mg Film-coated Tablets Summary of Product Characteristics (SmPC) (emc) Onglyza 2.5mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Trajenta 5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Alogliptin 12.5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc)
The incidence of major adverse limb events was lower in patients who received GLP-1R agonists than in those who received an SGLT-2 inhibitor
Mounjaro Dosing Progression Weeks 1-4: 2.5 mg weekly (starter dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly Weeks 17-20: 12.5 mg weekly Weeks 21+: 15 mg weekly (maximum dose) Mounjaros titration schedule is longer and involves more dose steps
